Systems Outcomes and Quality in Chronic Disease and Rehabilitation, Research Enhancement Award Program, Providence Veterans Administration (VA) Medical Center, Providence, RI, USA.
Ann Pharmacother. 2011 Nov;45(11):1346-55. doi: 10.1345/aph.1Q212. Epub 2011 Oct 25.
Depression is associated with poor glycemic control, increased number of microvascular and macrovascular complications, functional impairment, mortality, and 4.5 times higher total health care costs in patients with diabetes. Shared medical appointments (SMAs) may be an effective method to attain national guideline recommendations for glycemic control in diabetes for patients with depression through peer support, counseling, problem solving, and improved access to care.
To test the efficacy as assessed by attainment of a hemoglobin A(1c) (A1C) <7% of pharmacist-led group SMA visits, Veterans Affairs Multidisciplinary Education in Diabetes and Intervention for Cardiac Risk Reduction in Depression (VA-MEDIC-D), in patients with type 2 diabetes mellitus.
This was a randomized controlled trial of VA-MEDIC-D added to standard care versus standard care alone in depressed patients with diabetes with A1C >6.5%. VA-MEDIC-D consisted of 4 once-weekly, 2-hour sessions followed by 5 monthly 90-minute group sessions. Each SMA session consisted of multidisciplinary education and pharmacist-led behavioral and pharmacologic interventions for diabetes, lipids, smoking, and blood pressure. No pharmacologic interventions for depression were provided. The change in the proportion of participants who achieved an A1C <7% at 6 months was compared.
Compared to standard care (n = 44), a lower proportion of patients in VA-MEDIC-D (n = 44) had systolic blood pressure (SBP) <130 mm Hg at baseline, but were similar in other cardiovascular risk factors and psychiatric comorbidity. The change in the proportion of participants achieving an A1C <7% was greater in the VA-MEDIC-D arm than in the standard care arm (29.6% vs 11.9%), with odds ratio 3.6 (95% CI 1.1 to 12.3). VA-MEDIC-D participants also achieved significant reductions in SBP, low-density lipoprotein cholesterol, and non-high-density lipoprotein (HDL) cholesterol from baseline, whereas significant reductions were attained only in non-HDL cholesterol with standard care. There was no significant change in depressive symptoms for either arm.
Pharmacist-led group SMA visits are efficacious in attainment of glycemic control in patients with diabetes and depression without change in depression symptoms.
抑郁与血糖控制不佳、微血管和大血管并发症增多、功能障碍、死亡率有关,在糖尿病患者中,医疗总费用增加 4.5 倍。共同医疗预约(SMA)可能是一种通过同伴支持、咨询、解决问题和改善医疗服务获取途径,实现国家指南推荐的糖尿病患者血糖控制目标的有效方法。
评估药剂师主导的 SMA 就诊在实现血红蛋白 A1c(A1C)<7%方面的疗效,该研究在退伍军人事务部多学科糖尿病教育和抑郁中心心脏风险降低干预(VA-MEDIC-D)中,对 2 型糖尿病伴抑郁的患者进行测试。
这是一项 VA-MEDIC-D 联合标准护理与单纯标准护理治疗糖尿病伴 A1C>6.5%的抑郁患者的随机对照试验。VA-MEDIC-D 由 4 次每周 2 小时的课程和随后的 5 次每月 90 分钟的小组课程组成。每个 SMA 课程都包括多学科教育以及药剂师主导的针对糖尿病、血脂、吸烟和血压的行为和药物干预。没有提供针对抑郁的药物干预。比较了 6 个月时达到 A1C<7%的参与者比例的变化。
与标准护理组(n=44)相比,VA-MEDIC-D 组(n=44)的收缩压(SBP)<130mmHg 的患者比例较低,但在其他心血管危险因素和精神共病方面相似。VA-MEDIC-D 组达到 A1C<7%的参与者比例变化大于标准护理组(29.6%比 11.9%),优势比为 3.6(95%CI 1.1 至 12.3)。VA-MEDIC-D 组参与者的 SBP、低密度脂蛋白胆固醇和非高密度脂蛋白(HDL)胆固醇也从基线显著降低,而标准护理组仅非 HDL 胆固醇显著降低。两组的抑郁症状均无显著变化。
药剂师主导的小组 SMA 就诊在实现糖尿病和抑郁患者的血糖控制方面是有效的,而不会改变抑郁症状。